[AMGN] Amgen Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 147.55 Change: 1.19 (0.81%)
Ext. hours: Change: 0 (0%)

chart AMGN

Refresh chart

Strongest Trends Summary For AMGN

AMGN is in the medium-term up 15% above S&P in 1 month and down -9% below S&P in 1 year. In the long-term up 315% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate

Fundamental Ratios
Shares Outstanding EPS10.63 EPS Growth - 4 Quarters-5.54% EPS Growth - Q/Q23.37%
EPS Growth - Y/Y-9.79% Sales Growth - 4 Quarters -2.84% Sales Growth - Q/Q-5.59% P/E15.28
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA8.28% ROE21.53% ROI9.63%
Current Ratio5.53 Quick Ratio5.11 Long Term Debt/Equity1.04 Debt Ratio0.24
Gross Margin78.78% Operating Margin33.29% Net Profit Margin27.74% Dividend Payout Ratio-34.86%
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.24 B Cash From Investing Activities-952 M Cash From Operating Activities1.33 B Gross Profit4.57 B
Net Profit1.65 B Operating Profit2.08 B Total Assets71.21 B Total Current Assets37.74 B
Total Current Liabilities6.89 B Total Debt31.95 B Total Liabilities43.73 B Total Revenue5.37 B
Technical Data
High 52 week206.65 Low 52 week165 Last close194.87 Last change5.95%
RSI76.37 Average true range5.08 Beta0.85 Volume2.05 M
Simple moving average 20 days8.76% Simple moving average 50 days8.94% Simple moving average 200 days5.51%
Performance Data
Performance Week4.82% Performance Month10.25% Performance Quart15.18% Performance Half5.58%
Performance Year0.68% Performance Year-to-date0.88% Volatility daily2% Volatility weekly4.47%
Volatility monthly9.16% Volatility yearly31.75% Relative Volume183.77% Average Volume2.88 M
New High New Low


2019-08-24 07:29:00 | 3 Reasons Why Amgen Could Actually Acquire Alexion

2019-08-23 16:10:39 | Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer

2019-08-23 15:26:18 | Amgen’s Alexion Acquisition: Does It Make Sense?

2019-08-23 10:36:02 | Amgen Presents Positive Data From Rituxan Biosimilar Study

2019-08-23 09:58:00 | Alexion Stock Is Slipping Because an Amgen Bid Looks Less Likely

2019-08-23 06:00:00 | A Pair of Rare Disease Biotech Concerns Worth a Good Look

2019-08-22 16:08:36 | Biotech Giant Amgen Could Be Nearing A Massive Takeover: Report

2019-08-22 13:11:00 | Alexion Higher on Spanish Report, Cited by Analyst, That Amgen Will Make Bid

2019-08-22 10:03:00 | Amgen Stock’s Recent Rally Will Continue. Here’s Why.

2019-08-22 09:00:01 | Amgen AMGN Moves to Buy: Rationale Behind the Upgrade

2019-08-22 09:00:00 | Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® Rituximab

2019-08-21 12:37:59 | Arrowhead Pharmaceuticals: Buy at the High?

2019-08-20 17:35:20 | Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster

2019-08-20 09:44:01 | Here's Why Allergan is Outperforming Its Industry Of Late

2019-08-19 16:23:07 | Why The 2 Biggest Biotech Stocks Were Just Hit With Downgrades

2019-08-19 13:10:00 | Amgen Stock’s Rally Has Come Too Far Too Fast, Analyst Says

2019-08-19 08:04:12 | AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

2019-08-19 07:19:00 | Amgen Declines Following Mizuho Downgrade to Neutral

2019-08-18 09:30:00 | Is Amgen a Buy?

2019-08-14 16:32:23 | Unforgettable and Uninvestable

2019-08-14 09:36:23 | Wednesday’s Vital Data: Amgen, American Airlines and Apple

2019-08-14 09:35:01 | Amgen AMGN Soars to 52-Week High, Time to Cash Out?

2019-08-14 09:28:01 | Top Ranked Income Stocks to Buy for August 14th

2019-08-14 09:21:01 | Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More

2019-08-14 08:34:12 | Zacks Industry Outlook Highlights: Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Vertex Pharmaceuticals and Alexion Pharmaceuticals

2019-08-13 16:45:18 | Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales

2019-08-13 10:48:02 | Here's Why Amgen Stock is Outperforming Its Industry Of Late

2019-08-13 10:43:02 | Mergers & Acquisitions Take Center Stage in Biotech Industry

2019-08-13 09:50:01 | Should Value Investors Choose Amgen AMGN Stock Now?

2019-08-13 09:30:01 | Is Amgen AMGN Outperforming Other Medical Stocks This Year?

2019-08-13 05:26:09 | Will Amgen Continue to Surge Higher?

2019-08-13 04:23:00 | Fear Not the Curve, Sizing Up Earnings and Ways to Play Amgen: Market Recon

2019-08-12 16:18:06 | The Biggest Biotech Stock Is Approaching A Breakout — Here's Why

2019-08-12 14:49:12 | Amgen wins U.S. patent battle on arthritis drug Enbrel

2019-08-12 14:41:31 | REFILE-US STOCKS-Wall Street slides on geopolitical, recession fears

2019-08-12 14:21:00 | Amgen stock gets boost from Friday ruling on Enbrel

2019-08-12 13:26:06 | US STOCKS-Wall Street slips on political tensions, recession fears

2019-08-12 13:14:38 | Top Analyst Reports: Amgen, Uber, Mondelez & More

2019-08-12 09:55:04 | US STOCKS-Wall Street slips as trade war stokes fears of recession

2019-08-12 09:44:01 | Amgen Wins Enbrel U.S. Patent Litigation Against Novartis

2019-08-12 09:31:00 | Amgen’s Court Win Could Mark ‘a New Dawn’ for the Stock

2019-08-12 09:30:01 | Company News For Aug 12, 2019

2019-08-12 09:07:00 | [video]Amgen Climbs After Winning Patent Case on Enbrel

2019-08-12 08:09:12 | Top Ranked Income Stocks to Buy for August 12th

2019-08-12 05:33:00 | Amgen Rises 5%

2019-08-09 16:48:35 | US STOCKS-Wall St end down amid more trade woes, high volatility

2019-08-09 16:05:00 | Amgen Wins Patent Case On Enbrel® etanercept

2019-08-09 11:35:00 | Amgen Rises 3%

2019-08-09 10:31:02 | Puma PBYI Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up

2019-08-09 07:26:48 | Here's What We Like About Amgen Inc. NASDAQ:AMGN's Upcoming Dividend